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oRIGINAL ARTICLE
Introduction: In the U.K. more than 40,000 people are diagnosed 
with lung cancer every year and an estimated 65,000 people are liv-
ing with lung cancer. The most effective follow-up strategy for these 
patients is undetermined. This article reports a systematic review of 
studies comparing different follow-up strategies for patients with 
lung cancer.
Methods: We searched Medline, Premedline, Embase, Cochrane 
Library, Cinahl, BNI, Psychinfo, Amed, Web of Science (SCI & 
SSCI), and Biomed Central and included any original study pub-
lished in English comparing one type of follow-up strategy to 
another in patients with lung cancer who had received treatment 
with curative or palliative intent and/or best supportive care. 
Studies were included if there were 50 patients or more per fol-
low-up group.
Results: of the four included studies that compared different fol-
low-up strategies in patients with lung cancer, one was a random-
ized controlled trial and three were retrospective. The studies all 
examined different follow-up strategies and tended to be marked by 
various limitations. No formal data synthesis was therefore possible. 
However, in one article there was some evidence that regular review 
was associated with less emergency-department crisis attendances 
than symptom-generated review.
Conclusions: The included studies were marked by a number 
of methodological compromises. on the basis of the reported 
body of evidence it is therefore not possible to make any firm 
conclusions about the most effective follow-up strategy but the 
review has identified a need for urgent research into all aspects 
of follow-up.
Key Words: Lung cancer, Lung neoplasm, Follow-up, After care, 
Posttreatment, Surveillance.
(J Thorac Oncol. 2012;7: 821–824)
In the U.K. in 2008, there were 40,816 cases of lung cancer recorded by registries. In both men and women, lung cancer 
is the second-most common cancer and has the highest mor-
tality in both groups with more than 33,500 deaths per year1. 
Survival is short but improving. More patients are receiving 
treatment that is becoming more complex. Despite this, there 
are no evidence-based recommendations on the most effective 
follow-up models for patients. The value of follow-up in lung 
cancer includes monitoring of treatment outcomes and com-
plications, detection of relapse and recurrence, detection and 
management of symptoms, provision of information, and pro-
vision of supportive and palliative care. The emphasis on the 
purpose of follow-up will differ depending on which modal-
ity of treatment has been given. When radical treatment has 
been given, there will be more emphasis on the detection of 
recurrent disease, whereas if there has been active palliative 
treatment, there may be a focus on the detection of disease 
progression and symptom control. If no active treatment has 
been offered then follow-up will be directed toward symp-
tom control. Where patients with lung cancer are admitted to 
hospital, around 30% of them use the emergency-department 
route. one of the key aims of the National Cancer Strategy is 
to reduce this, and follow-up may be important here.
The aim of this study was to systematically compare the 
long- and short-term outcomes of patients who have received 
different follow-up strategies after treatment with curative or 
palliative intent or best supportive care for lung cancer.
MATERIALS AND METHODS
Criteria for Considering Studies in This Review
Any original study published in full in English compar-
ing one type of follow-up strategy to another follow-up strat-
egy in patients with lung cancer who have received treatment 
with either curative or palliative intent or who have received 
best supportive care, and which have 50 patients or more per 
follow-up group has been included for this review. For the 
purposes of this systematic review, we have used the oxford 
Dictionary of English (second edition, 2003) definition of fol-
low-up, i.e., follow up is the “further examination or observa-
tion of a patient to monitor the success of earlier treatment.”
Search Methods for Identification of Studies
The following databases were searched: Medline (1948 
to September 28, 2011), Premedline (September 26, 2011), 
Embase (1980 to September 28, 2011), Cochrane Library 
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(September 28, 2011), Cinahl (1982 to September 28, 
2011), BNI (1985–September 28, 2011), Psychinfo (1806 to 
September 28, 2011), Amed (1985 to September 28, 2011), 
Web of Science (SCI 1899 to September 28, 2011 & SSCI 
1956 to September 28, 2011), and Biomed Central (as per 
database) using the following oVID Medline search strategy 
(adapted to each database):
 1. Exp Lung Neoplasms/
 2. (lung adj (neoplasm$ or cancer$ or carcinoma$ or ade-
nocarcinoma$ or angiosarcoma$ or chrondosarcoma$ or 
sarcoma$ or teratoma$ or lymphoma$ or blastoma$ or 
microcytic$ or carcinogenesis or tumour$ or tumor$ or 
metast$)).ti,ab.
 3. (NSCL or SCLC).ti,ab.
 4. or/1-3
 5. exp Aftercare/
 6. (aftercare or after-care or followup or follow-up or 
surveillance).m_titl.
 7. ((post-treatment or posttreatment) adj1 evaluation$).
mp. [mp=title, original title, abstract, name of substance 
word, subject heading word, unique identifier]
 8. ((post-treatment or posttreatment) adj1 care).mp. 
[mp=title, original title, abstract, name of substance 
word, subject heading word, unique identifier]
 9. ((post-treatment or posttreatment) adj1 monitoring).
mp. [mp=title, original title, abstract, name of substance 
word, subject heading word, unique identifier]
10. or/5-9
11. 4 and 10
Data Analysis
The results of the computerized search were imported 
into a database that was screened for relevant and potentially 
relevant studies by one of the authors (M.S.H.), who also per-
formed the data extraction from the final group of included 
studies. The relevance of the potentially relevant studies was 
confirmed by consensus between two of the authors (M.S.H. and 
D.R.B.) who also both assessed the quality of the studies. The 
feasibility of meta-analysis was explored, although it was not 
expected that a meta-analysis would be possible because of the 
anticipated between-study variation, in which case the results of 
the included studies would be summarized narratively.
RESULTS
Search Results
The search of all the databases identified 2972 (before 
de-duplication) possibly relevant articles of which 2930 were 
excluded based on title and abstract and 42 were obtained for 
full text review. of these 42 articles, 38 were excluded as they 
did not meet the inclusion criteria and 4 were identified for 
inclusion in the present review2–5.
Characteristics and Findings of the Studies
Moore et al2. randomized 203 patients who had com-
pleted their initial treatment for lung cancer of any stage and 
type and who were expected to live for 3 months or more to 
receive either conventional follow-up or follow-up by lung 
cancer specialist nurses. Conventional follow-up consisted 
of one posttreatment appointment and then routine outpatient 
appointments every 2 to 3 months for medical assessments 
and investigations to monitor disease progression in addi-
tion to need-based appointments. Although it is not explic-
itly reported who followed up the patients allocated to receive 
conventional follow-up, given the breadth of the sample it 
is highly likely that a number of different specialists were 
involved in the conventional follow-up (e.g., medical and clin-
ical oncologists, and thoracic surgeons). Nurse-led follow-up 
consisted of monthly assessment either over the telephone or 
in a nurse-led clinic to identify signs of disease progression, 
symptoms warranting intervention, or serious complications. 
The main focus of the clinical nurse specialist was to provide 
information and support and coordinate input from other ser-
vices or agencies.
Median survival did not differ between the follow-up 
groups, but median time to symptomatic progression was 
shorter in the nurse-led follow-up group (6 months) than in 
the conventional follow-up group (10.2 months), although 
this difference was not evident in time to objective progres-
sion, which did not differ between the groups. Although 
quality of life was comparable between the groups at 3, 
6, and 12 months (when the alpha-level is corrected for 
multiple comparisons), the patients who received nurse-
led follow up reported at 3 and 6 months that they were 
generally more satisfied with their care than the patients 
who received conventional follow up (again with alpha-
level correction for multiple comparisons). The groups did 
not differ in the number of visits to general practitioners, 
home visits by general practitioners, admissions to hos-
pital/hospice, scans since previous visit, the number of 
radiographs taken at 3 and 6 months, rate of radiotherapy 
treatment at 3 months, consultations with other medical 
staff/specialists/therapists, the number of patients who 
died at home (rather than in hospital/hospice), or in the use 
of social series, district nurse, Macmillan nurse or home-
care team, other community therapist, chemotherapy or 
surgery since previous assessment, nor did the groups dif-
fer in the rate of changes in drugs/new drugs since previ-
ous assessment (with alpha-level adjustment for multiple 
comparisons). The authors did, however, find in a trend 
analysis that the patients who received nurse-led follow-up 
had significantly less consultations with a hospital doctor 
(at 3 months) than the patients who received conventional 
follow-up.
Although Moore et al2 provide no details about the 
method of randomization and whether allocation concealment 
was employed, this study seems to be adequately powered to 
detect differences (at least) in primary outcomes (i.e., quality 
of life and patient satisfaction at 3 months) and the follow-up 
groups were comparable at baseline.
In a sample of 1398 retrospectively recruited patients 
who had undergone surgery for non–small cell lung cancer, 
Nakamura et al3 assessed whether survival differed between 
patients who were followed up postoperatively by thoracic 
surgeons (n = 846; 630 men) and patients who were followed 
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up postoperatively by chest physicians (n = 552; 384 men). 
Although there seemed to have been no protocol-driven fol-
low-up programs, follow-up by thoracic surgeons included 
physical examination and chest radiograph at 1 month after 
the surgery and then every 3 to 4 months for the next 3 years. 
In addition to these procedures, follow-up by chest physicians 
also included chest computed tomography every 6 months. It 
was the case for both follow-up groups that the frequency of 
other scans and follow-up visits depended on the doctors in 
charge of follow-up. Nakamura et al3 found that follow-up by 
thoracic surgeons conferred an independent increased hazard 
of death relative to follow-up by chest physicians (hazard ratio 
= 1.279). However, this result is confounded by the differences 
in follow-up procedures between the groups (e.g., unlike the 
patients who were followed up by thoracic surgeons, the 
patients who were followed up by chest physicians received 
regular chest CTs) and it is not possible to further unravel this 
confound because of the absence of additional details regard-
ing the exact follow-up interventions received by the patient 
groups.
In a retrospective study, Virgo et al4 examined in 
patients with stage-I to -IIIA lung cancer treated with cura-
tive intent whether a number of outcomes differed between 
those who received an intensive follow-up schedule (n = 120) 
and those who received a nonintensive follow-up schedule 
(n = 62). Length of follow-up and baseline characteristics of 
the groups were comparable with the following exceptions: 
the intensively followed-up group had significantly more 
comorbidities and a significantly longer disease-free inter-
val than the nonintensively followed-up patients. Intensity 
of follow-up did not significantly influence time to detection 
of local or regional recurrences, time to detection of second 
primary, time to detection of metastases, survival (for all 
patients or for stage-I patients only), survival after detection 
of local or regional recurrence, survival after detection of 
second primary, survival after detection of metastases, local 
and regional recurrences, second primaries, metastases, and 
multiple metastases.
Younes et al5 assessed retrospectively whether patient 
outcomes differed between a strict follow-up schedule and 
a symptom-based follow-up schedule in patients who had 
undergone complete operative and pathologic resection of 
non–small cell lung cancer. The strict follow-up schedule 
consisted of physical examinations (at weeks 1 and 3, at 2 
months, then bimonthly for the first 6 months and subse-
quently every 3 months until 2 years had elapsed), chest 
radiographs (at weeks 1 and 3 and then at 2, 4, 9, 15, and 
24 months), and liver functions tests (at 1 and 2 years). The 
patients in the symptom-based follow-up group received a 
maximum of 3 consultations per year in the first 2 years after 
surgery. The baseline characteristics of the groups were com-
parable. Disease-free survival and survival after recurrence 
did not differ between the strict (n = 67; 55 men) and symp-
tom-based (n = 63; 56 men) follow-up groups, but the patients 
who received symptom-based follow-up experienced more 
(health problem) episodes detected in the emergency room, 
had more health problems treated on an inpatient basis, and 
spent more days as an inpatient for health problems compared 
to the patients receiving a strict follow-up schedule, who had 
more health problems treated on an outpatient basis.
DISCUSSION
Evidence on the effectiveness of follow-up for lung 
cancer patients is limited both because of the design and 
number of the studies examining different follow-up models/
strategies. Three of the four included studies were retrospec-
tive and marked by a number of limitations that render the 
results unreliable (e.g., lack of procedural details, group dif-
ferences in baseline clinical characteristics, and small sample 
sizes). In addition, the follow-up strategies employed differed 
between all four studies, which makes formal data synthesis 
impossible.
The paucity of evidence precludes firm evidence-based 
recommendations about the best follow-up strategy for lung 
cancer patients. However, the study by Younes et al5 does 
provide tentative evidence for an effect that seems intuitively 
correct—that is, that regular follow-up results in fewer crisis-
driven health-related episodes. Such episodes are distressing 
to patients and carers, not least because the emergency admis-
sion process is often difficult and, in the U.K. at least, often 
leads to inpatient management by nonspecialists,6,7 which, in 
turn, is likely to be associated with higher costs. However, the 
evidence has not permitted an analysis of cost effectiveness.
The randomized controlled trial by Moore et al2 con-
stituted the best available evidence of the current topic and 
showed that follow-up led by specialist clinical nurses is asso-
ciated with high levels of patient satisfaction and acceptability, 
and with comparable levels of quality of life, median survival, 
and time to progression.
None of the included studies examined the use of spe-
cific tests/interventions in the context of follow-up (e.g., vari-
ous imaging modalities such as computed tomography, chest 
radiograph and positron emission tomography, sputum cytol-
ogy, bronchoscopy, and serum markers) although the use of 
some tests seemed to differ between some of the follow-up 
groups (e.g., 2–3). Systematic examination of the value of dif-
ferent tests and the frequency with which they should be used 
in follow-up of patients diagnosed with lung cancer is needed 
to establish the most effective follow-up strategy. The value 
of individual tests is likely to depend on whether the patient 
is followed up after intervention(s) with palliative or curative 
intent and the timing of the tests can fruitfully be informed by 
what is already known about the pattern of first recurrence, 
metastatic spread, and side effects following treatment (cf. ref. 
8). Moreover, added value of optimal routine follow-up may 
also be observed in earlier identification of second cancers 
in the thorax and aerodigestive traction. Thus, it is clear that 
more prospective research is needed in this area, ideally in the 
form of well-designed randomized controlled trials comparing 
different follow-up strategies in patients who have received 
treatment for lung cancer.
Implications for Practice
Despite the absence of a firm evidence base on which 
to make recommendations for practice, it is important that the 
issue of providing good follow-up for patients must not be 
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neglected. The wishes of patients and carers should always be 
a priority in offering follow-up. Where evidence is lacking, 
we have to rely on expert opinion. The most recent recom-
mendations on follow-up can be found in the recently updated 
National Institute for Health and Clinical Excellence guide-
line on the Diagnosis and Treatment of Lung Cancer,9 which 
are based on this systematic evidence review and expert opin-
ion (see also refs. 10 and 11):
 offer all patients an initial specialist follow-up appoint-• 
ment within 6 weeks of completing treatment to discuss 
ongoing care, and regular appointments thereafter rather 
than relying on patients requesting appointments when 
they experience symptoms.
 offer protocol-driven follow-up led by a lung cancer • 
clinical nurse specialist as an option for patients with a 
life expectancy of more than 3 months.
 Ensure that patients know how to contact the lung cancer • 
clinical nurse specialist involved in their care between 
their scheduled hospital visits.
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